Advances in Managing Brain Metastases in RCC
In Partnership With
Manmeet Ahluwalia, MD, MBA, FASCO, discusses the prevalence of brain metastases in patients with primary renal cell carcinoma.
Manmeet Ahluwalia, MD, MBA, FASCO, chief scientific officer, chief of medical oncology, deputy director, and Fernandez Family endowed chair in cancer research at the Baptist Health Miami Cancer Institute, discusses the prevalence of brain metastases in patients with primary renal cell carcinoma (RCC).
According to Ahluwalia, the outcomes for patients with kidney cancer has improved over the years, yet kidney cancer currently ranks as the fourth most common cancer to metastasize to the brain after lung cancer, breast cancer, and melanoma. While he notes that it can be challenging to predict the exact proportion of patients with kidney cancer who will develop brain metastases, Ahluwalia estimates it to be approximately 10% to 15% of patients with stage IV disease.
Findings presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting revealed that combining stereotactic radiosurgery with immunotherapy significantly improves overall survival in patients with RCC and brain metastases. The results highlight the potential of this combination strategy to enhance treatment outcomes in this challenging clinical setting, offering new hope for patients with advanced disease.
Transcription:
0:10 | As the outcomes of kidney cancer have improved, we do know that the brain is a sanctuary site, and we are seeing an increasing incidence of brain metastases in patients with kidney cancer. In fact, kidney cancer has become the fourth most common cancer that goes to the brain after lung cancer, breast cancer and melanoma.
0:30 | However, it is difficult to predict exactly what proportion of patients with kidney cancer will get brain metastases. We think it is probably in the ballpark of 10% to 15% with stage IV kidney cancer.
REFERENCE:
Podder V, Ganiyani MA, Ahmad S, et al. Treatment outcomes of brain metastasis from primary renal cell carcinoma in United States: A National Cancer Database analysis. J Clin Oncol. 42, 2024 (suppl 16; abstr 4561). doi: 10.1200/JCO.2024.42.16_suppl.4561
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Considering How Favorable Risk Affects Treatment in ccRCC
January 3rd 2025During a Case-Based Roundtable® event, Daniel J. George, MD, discusses how often community oncology participants see patients with favorable-risk vs intermediate- or high-risk RCC, and how it changes their treatment options.
Read More
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Could Triapine With Lutetium 177 Dotatate Improve Outcomes for Neuroendocrine Tumors?
December 30th 2024Aman Chauhan, MD, highlights an ongoing phase 2 trial exploring the combination of triapine, a radiation sensitizer, with lutetium 177 dotatate for treating well-differentiated somatostatin receptor–-positive neuroendocrine tumors.
Read More
